SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / May 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
The Law Offices of Frank R. Cruz announces an investigation on behalf of CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) investors concerning the Company and its officers’ possible violations of federal securities laws.
LOS ANGELES, CA / ACCESSWIRE / May 27, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against CytomX Therapeutics, Inc. ("CytomX" ...
Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. (“CytomX” or the “Company”) (CTMX) and certain of its officers. The class action, filed in United States District Court for the Northern District of California, and indexed under 20-cv-03432, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired CytomX securities between May 17, 2018, and May 13, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
New York, New York--(Newsfile Corp. - May 27, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX") between May 17, 2018 and May 13, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Northern District of California. To get ...
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytomX Therapeutics, Inc. (CTMX) on Behalf of Investors
NEW YORK, NY / ACCESSWIRE / May 26, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
New York, New York--(Newsfile Corp. - May 27, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc. (NASDAQ: CTMX) alleging that the Company violated federal securities laws.Class Period: May 17, 2018 and May 13, 2020Lead Plaintiff Deadline: July 20, 2020Learn more about your recoverable losses in DNK:http://www.kleinstocklaw.com/pslra-1/cytomx-therapeutics-inc-loss-submission-form?id=6941&from=5The filed complaint alleges that CytomX Therapeutics, Inc. made materially false and/or misleading statements ...
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) securities between May 17, 2018, and May 13, 2020, inclusive (the "Class Period"). CytomX investors have until July 20, 2020 to file a lead plaintiff motion.
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Elanco Animal Health Incorporated (ELAN), Ryder System, Inc. (NYSE:R), CytomX Therapeutics, Inc. (CTMX), and Hamilton Beach Brands Holding Company (HBB). Elanco is an animal health company that develops, manufactures, and markets products for companion and food animals. Its four primary categories are: Companion Animal Disease Prevention (“CA Disease Prevention”), which offers parasiticides that protect pets from worms, fleas and ticks; Companion Animal Therapeutics (“CA Therapeutics”), which offers treatments for pain, osteoarthritis, otitis, as well as cardiovascular and dermatology indications; Food Animal Future Protein & Health (“FA Future Protein & Health”), which includes vaccines, nutritional enzymes, and antibiotics; and Food Animal Ruminants & Swine (“FA Ruminants & Swine”), which develops food animal products used extensively in ruminant and swine production.
New York, New York--(Newsfile Corp. - May 27, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or the "Company") of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi logoIf you invested in CytomX stock or options between May 17, 2018 and May ...
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against CytomX Therapeutics, Inc. (“CytomX” or the “Company”) (CTMX) in the United States District Court for the Northern District of California on behalf of those who purchased or acquired the securities of CytomX between May 17, 2018, and May 13, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for CytomX investors under the federal securities laws. The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) CytomX had downplayed issues with CX-072’s efficacy observed in the PROCLAIM-CX-072 clinical program; (2) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CytomX Therapeutics, Inc. (CTMX) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. Investors
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...